Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Preventing Cross-Contamination of Samples – V 2.0

Posted on By

BA-BE Studies: SOP for Preventing Cross-Contamination of Samples – V 2.0

Standard Operating Procedure for Preventing Cross-Contamination of Samples in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/114/2025
Supersedes SOP/BA-BE/114/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a robust and standardized procedure for the prevention of cross-contamination of clinical samples during collection, processing, labeling, storage, and transport in Bioavailability/Bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all personnel involved in clinical sample handling, including collection, separation, labeling, aliquoting, storage, and transfer processes conducted at clinical and bioanalytical facilities.

3. Responsibilities

  • Phlebotomist: Collects samples using sterile equipment and ensures no reuse of consumables.
  • Processing Technician: Handles only one subject’s samples at a time and disinfects work area between batches.
  • Quality Assurance (QA): Conducts periodic audits and reviews sample tracking logs for compliance.
  • Bioanalytical Staff: Verifies sample integrity upon receipt and inspects packaging for leaks or cross-labeling.
See also  BA-BE Studies: SOP for Fasted vs Fed Study Design Selection - V 2.0

4. Accountability

The Head of Clinical Laboratory Operations is accountable for ensuring that all measures to prevent cross-contamination are in place, implemented, and periodically reviewed.

5. Procedure

5.1 General Laboratory Practices

  1. All sample handling personnel must:
    • Wear gloves, masks, and lab coats at all times
    • Change gloves between subjects
    • Disinfect benchtops and centrifuges with 70% IPA before and after use

5.2 Sample Collection

  1. Use pre-labeled, single-use vacutainers or blood collection tubes for each subject.
  2. Maintain individual sample trays to avoid mixing of subject IDs.
  3. Complete Annexure-1: Sample Collection Checklist for each subject at each timepoint.

5.3 Sample Processing

  1. Process samples from one subject at a time.
  2. Aliquot using separate, disposable pipette tips for each sample.
  3. Ensure one operator handles both labeling and aliquoting to prevent misidentification.
  4. Record processing times and personnel on Annexure-2: Sample Processing Log.
See also  BA-BE Studies: SOP for IMP Accountability Logs - V 2.0

5.4 Storage and Segregation

  1. Store samples in properly labeled cryoboxes, with:
    • Unique volunteer ID
    • Timepoint
    • Date
  2. Do not mix samples from different studies in the same storage rack or freezer compartment.

5.5 Sample Transfer

  1. Use sealed containers with absorbent materials for inter-department or site transfer.
  2. Document chain of custody using Annexure-3: Sample Transfer Log.
  3. Inspect each sample’s label upon receipt and verify against manifest.

5.6 Deviation Handling

  1. Any suspicion or confirmed instance of contamination must be reported to QA immediately.
  2. Initiate deviation report using Annexure-4: Contamination Incident Report.
  3. Perform root cause analysis and implement CAPA.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • QA: Quality Assurance
  • IPA: Isopropyl Alcohol
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Sample Collection Checklist – Annexure-1
  2. Sample Processing Log – Annexure-2
  3. Sample Transfer Log – Annexure-3
  4. Contamination Incident Report – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • WHO Guidelines on Biological Sample Handling
  • Schedule Y – Drugs and Cosmetics Rules
See also  BA-BE Studies: SOP for Volunteer Identification and Screening Logs - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Sample Collection Checklist

Volunteer ID Timepoint Tube Label Verified Gloves Changed Phlebotomist Signature
VOL-114-007 0 hr Yes Yes Sunita Reddy

Annexure-2: Sample Processing Log

Volunteer ID Start Time End Time Processed By Remarks
VOL-114-007 10:00 10:12 Rajesh Kumar None

Annexure-3: Sample Transfer Log

Date Transferred By Received By Container ID Status
17/04/2025 Ajay Verma Meena Joshi BOX-22 Intact

Annexure-4: Contamination Incident Report

Date Volunteer ID Description Root Cause CAPA
16/04/2025 VOL-114-005 Sample mixed with wrong label Label not double-checked Staff retraining, checklist revision

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP Regulatory Requirement QA Head
17/04/2025 2.0 Added checklist annexures and clarified glove and pipette usage Audit Findings QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Aerosol: SOP for Documenting Equipment Qualification Reports – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version